UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 79

Sortiert nach

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

Annals of oncology, 2017-10, Vol.28 (10), p.2436-2442

2017

Volltextzugriff (PDF)

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)

Annals of oncology, 2009-04, Vol.20 (4), p.674-680

2009

Volltextzugriff (PDF)

OC-0451 ACCORD 12 TRIAL OF NEOADJUVANT TREATMENT IN RECTAL CANCER: CLINICAL RESULTS AT 3 YEARS. ON BEHALF OF PRODIGE GROUP

Radiotherapy and oncology, 2012-05, Vol.103, p.S180-S180

2012

Volltextzugriff (PDF)

Two-part statistics with paired data

Statistics in medicine, 2005-05, Vol.24 (9), p.1435-1448

2005

Volltextzugriff (PDF)

OC-0480: Five-year clinical outcome of the Phase III ACCORD 12 neoadjuvant trial in rectal cancer

Radiotherapy and oncology, 2016-04, Vol.119, p.S230-S230

2016

Volltextzugriff (PDF)

OC-0419: Clinical complete response in rectal cancer to increase conservative treatment. ACCORD12 randomized trial

Radiotherapy and oncology, 2013-03, Vol.106, p.S161-S161

2013

Volltextzugriff (PDF)

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

The New England journal of medicine, 2011-05, Vol.364 (19), p.1817-1825

2011

Volltextzugriff (PDF)

ACCORD12/0405-Prodige 2 Phase III Trial Neoadjuvant Treatment in Rectal Cancer: Results after 3 Years of Follow-up

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S2-S2

2011

Volltextzugriff (PDF)

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-05, Vol.26 (5), p.873-879

2015

Volltextzugriff (PDF)

Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial

Journal of clinical oncology, 2010-05, Vol.28 (15_suppl), p.4010-4010

2010

Volltextzugriff (PDF)

Results of the Accord 12/0405 Prodige2 Randomized Trial are in Favor of Benefit of Radiation Dose Intensification in the Neoadjuvant Treatment of T3–4 M0 Rectal Cancer

International journal of radiation oncology, biology, physics, 2009, Vol.75 (3), p.S6-S6

2009

Volltextzugriff (PDF)

Accelerated and Partial Breast Irradiation in Elderly Women: Gerico-03 Phase II Trial Results

International journal of radiation oncology, biology, physics, 2009, Vol.75 (3), p.S222-S222

2009

Volltextzugriff (PDF)

Impact on autonomy of biweekly docetaxel as first-line chemotherapy (CT) regimen in elderly patients with metastatic breast cancer (MBC) – A FNCLCC Gerico Group Phase II multicentre trial

Critical reviews in oncology/hematology, 2008-10, Vol.68, p.S45-S45

2008

Volltextzugriff (PDF)

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

Oncotarget, 2016-12, Vol.7 (50), p.82953-82960

2016

Volltextzugriff (PDF)

O7 Feasibility, reproducibility and impact on functional autonomy of a post-operative accelerated and partial breast irradiation in elderly women: GERICO-03 Phase II Trial results

Critical reviews in oncology/hematology, 2009, Vol.72 (1), p.S16-S17

2009

Volltextzugriff (PDF)

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Annals of oncology, 2015-05, Vol.26 (5), p.865-872

2015

Volltextzugriff (PDF)

A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)

Journal of clinical oncology, 2005-06, Vol.23 (16_suppl), p.3502-3502

2005

Volltextzugriff (PDF)

Modèles à effets aléatoires pour l’analyse longitudinale de la qualité de vie relative à la santé dans l’essai randomisé PRODIGE 4/ACCORD 11

Revue d'épidémiologie et de santé publique, 2014-08, Vol.62 (S4), p.S117-S118

2014

Volltextzugriff (PDF)

Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan

Journal of clinical oncology, 2005-01, Vol.23 (3), p.650; author reply 650-650

2005

Volltextzugriff (PDF)

Abstract P4-17-02: Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P4-P4-17-02

2013

Volltextzugriff (PDF)

Éditorial

Revue d'épidémiologie et de santé publique, 2015-05, Vol.63, p.S35-S36

2015

Volltextzugriff (PDF)

Abstract P6-06-22: Outcome of patients with intrinsic hypersensitivity to ionizing radiation and included in the COHORT phase II randomized trial evaluating concurrent or sequential letrozole with adjuvant breast radiotherapy

Cancer research (Chicago, Ill.), 2013-12, Vol.73 (24_Supplement), p.P6-P6-06-22

2013

Volltextzugriff (PDF)

Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial

Journal of clinical oncology, 2011-05, Vol.29 (15_suppl), p.TPS178-TPS178

2011

Volltextzugriff (PDF)

Impact de l’effet “Response Shift” sur l’analyse longitudinale de la qualité de vie relative à la santé dans les essais cliniques en cancérologie : une étude de simulation

Revue d'épidémiologie et de santé publique, 2015-05, Vol.63, p.S49-S49

2015

Volltextzugriff (PDF)

Comparaison de trois méthodes statistiques pour l’analyse longitudinale de la qualité de vie relative à la santé en cancérologie : une étude de simulation

Revue d'épidémiologie et de santé publique, 2014-08, Vol.62, p.S132-S132

2014

Volltextzugriff (PDF)

1 – 25 von 79

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(74)
Mit Volltextzugriff
(78)

Publikationsform

Artikel
(79)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(29)
Science & Technology
(29)
Life Sciences & Biomedicine
(27)
Oncology
(24)
Female
(23)
Male
(17)
Middle Aged
(16)
Aged
(15)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(15)
Hematology, Oncology And Palliative Medicine
(15)
Life Sciences
(15)
Adult
(12)
Disease-Free Survival
(12)
Fluorouracil - Administration & Dosage
(10)
Deoxycytidine - Analogs & Derivatives
(9)
Treatment Outcome
(9)
Tumors
(9)
Cancer
(8)
Organoplatinum Compounds - Administration & Dosage
(8)
Santé Publique Et Épidémiologie
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer

A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02/FFCD9802)

OC-0451 ACCORD 12 TRIAL OF NEOADJUVANT TREATMENT IN RECTAL CANCER: CLINICAL RESULTS AT 3 YEARS. ON BEHALF OF PRODIGE GROUP

Two-part statistics with paired data

OC-0480: Five-year clinical outcome of the Phase III ACCORD 12 neoadjuvant trial in rectal cancer

OC-0419: Clinical complete response in rectal cancer to increase conservative treatment. ACCORD12 randomized trial

FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer

ACCORD12/0405-Prodige 2 Phase III Trial Neoadjuvant Treatment in Rectal Cancer: Results after 3 Years of Follow-up

Guidelines for time-to-event end point definitions in breast cancer trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

Randomized phase III trial comparing FOLFIRINOX (F: 5FU/leucovorin [LV], irinotecan [I], and oxaliplatin [O]) versus gemcitabine (G) as first-line treatment for metastatic pancreatic adenocarcinoma (MPA): Preplanned interim analysis results of the PRODIGE 4/ACCORD 11 trial

Results of the Accord 12/0405 Prodige2 Randomized Trial are in Favor of Benefit of Radiation Dose Intensification in the Neoadjuvant Treatment of T3–4 M0 Rectal Cancer

Accelerated and Partial Breast Irradiation in Elderly Women: Gerico-03 Phase II Trial Results

Impact on autonomy of biweekly docetaxel as first-line chemotherapy (CT) regimen in elderly patients with metastatic breast cancer (MBC) – A FNCLCC Gerico Group Phase II multicentre trial

An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma

O7 Feasibility, reproducibility and impact on functional autonomy of a post-operative accelerated and partial breast irradiation in elderly women: GERICO-03 Phase II Trial results

Guidelines for time-to-event end point definitions in sarcomas and gastrointestinal stromal tumors (GIST) trials: results of the DATECAN initiative (Definition for the Assessment of Time-to-event Endpoints in CANcer trials)

A phase III randomized trial of LV5FU2+CPT-11 vs. LV5FU2 alone in adjuvant high risk colon cancer (FNCLCC Accord02/FFCD9802)

Modèles à effets aléatoires pour l’analyse longitudinale de la qualité de vie relative à la santé dans l’essai randomisé PRODIGE 4/ACCORD 11

Relationship of serum bilirubin to toxicity in patients with metastatic colorectal cancer treated with single-agent high-dose irinotecan

Abstract P4-17-02: Guidelines for the definitions of time-to-event endpoints in randomized clinical trials: Results of the datecan project for breast group

Éditorial

Abstract P6-06-22: Outcome of patients with intrinsic hypersensitivity to ionizing radiation and included in the COHORT phase II randomized trial evaluating concurrent or sequential letrozole with adjuvant breast radiotherapy

Met or EGFR Inhibition in Gastroesophageal Adenocarcinoma (MEGA): FOLFOX alone or in combination with AMG 102 or panitumumab as first-line treatment in patients with advanced gastroesophageal adenocarcinoma: FNCLCC-FFCD-AGEO-GERCOR PRODIGE 17-ACCORD 20 randomized phase II trial

Impact de l’effet “Response Shift” sur l’analyse longitudinale de la qualité de vie relative à la santé dans les essais cliniques en cancérologie : une étude de simulation

Comparaison de trois méthodes statistiques pour l’analyse longitudinale de la qualité de vie relative à la santé en cancérologie : une étude de simulation

Suchergebnisse filtern